Independent Group Says New Glaxo Asthma Drug Far Too Expensive

An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines found the price of GlaxoSmithKline's new drug for severe asthma should be as much as 76% lower to justify its value, according to the group's latest draft report.